Centanafadine HCl
Catalog No: 21236
CAS Number: 923981-14-0
Purity: ≧98.0%
Centanafadine, also known as EB-1020, is an adrenergic uptake inhibitor and dopamine uptake inhibitor and serotonin uptake inhibitor. Centanafadine modulates norepinephrine, dopamine and, to a lesser extent, serotonin reuptake in a ratio of 1:6:14, respectively to improve focus, attention and executive function.
For research use only. We do not sell to patients.
Chemical Information
| Name | Centanafadine HCl |
|---|---|
| Iupac Chemical Name | (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochoride |
| Synonyms | EB-1020 ; EB 1020 ; EB1020 ; EB-1020 SR ; CTN SR ; Centanafadine |
| Molecular Formula | C15H16ClN |
| Molecular Weight | 245.75 |
| Smile | [H][C@@]12CNC[C@]1(C3=CC=C4C=CC=CC4=C3)C2.[H]Cl |
| InChiKey | ACVMJAJGCQUPKX-LIOBNPLQSA-N |
| InChi | InChI=1S/C15H15N.ClH/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15;/h1-7,14,16H,8-10H2;1H/t14-,15+;/m1./s1 |
| CAS Number | 923981-14-0 |
| Related CAS | 924012-43-1 (free base) 923981-14-0 (HCl) |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white solid to white solid |
|---|---|
| Purity | ≧98.0% |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation. |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2933999701 |
Coming soon.
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI. Pharmacological
characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020:
implications for treatment of attention-deficit hyperactivity disorder. Synapse.
2012 Jun;66(6):522-32. doi: 10.1002/syn.21538. Epub 2012 Feb 22. PubMed PMID:
22298359.
Chemical Structure
